Celecoxib/Ciprofloxacin Drug Asset Due Diligence Report 2026

This Celecoxib/Ciprofloxacin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

873

Registered trials

305

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Celecoxib/Ciprofloxacin can convert its Small molecule drug profile and Bacterial Top II x COX-2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Celecoxib/Ciprofloxacin (query alias: Celecoxib/Ciprofloxacin)
Modality / target	Small molecule drug; Bacterial Top II x COX-2; Bacterial DNA gyrase inhibitors, COX-2 inhibitors
Highest global status	Phase 2
Originator	Neurosense Therapeutics Ltd.
Active developers	Neurosense Therapeutics Ltd.

The MCP disease footprint includes Amyotrophic Lateral Sclerosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07820891	Phase 1	Not yet recruiting	24	Primary endpoint not disclosed in English source
NCT07809893	Phase 2	Recruiting	45	Primary endpoint not disclosed in English source
ChiCTR2600128768	Phase 4	Pending	65	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2; n=5; evaluation: Not stated in English source. Reported fields: Incidence of Dose Limiting Toxicities = 0 Pts ; Incidence of Dose Limiting Toxicities = 1 Pts

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial

Phase 2; n=110; evaluation: Positive. Reported fields: pCR = 89.0 % ( 78 - 96); pCR = 69.0 % ( 55 - 81)

Real world outcomes with neoadjuvant chemo-immuno-metronomic therapy in advanced head and neck squamous cell carcinoma (NeoLOCUS-Retro).

Not Applicable; n=43; evaluation: Positive. Reported fields: Conversion to radical-intent therapy = 69.8 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Celecoxib/Ciprofloxacin addresses Amyotrophic Lateral Sclerosis. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 6 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-03-05	SK chemicals signs distribution and marketing deal with Viatris Korea for three drugs	Approved	Financial terms not disclosed
2023-02-12	Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ from Collegium in the U.S. and Canada for the acute treatment of migraine	Approved	Financial terms not disclosed
2022-02-14	Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO